In patients undergoing hip replacement surgery, the recommended duration of treatment is 35 days. Apixabans package insert states that patients with atrial fibrillation may receive full dose apixaban 5 mg twice daily while on hemodialysis as long as they are under the age of 80 and weigh above 60 kg. Dec 24, 2018 the study reported that none of the patients who had available clinical data n 2238 had recurrent vte or stroke, though information surrounding follow. Pdf the use of anticoagulants in morbidly obesity patients. The majority of data pertaining to the dosing of lmwh in obese patients for vte prophylaxis has been collected from patients undergoing bariatric surgery, with enoxaparin being the most common agent assessed. An increased rate of stroke was observed following discontinuation of apixaban in clinical trials in patients with nonvalvular atrial fibrillation. If a patient is on dialysis and is above the age of 80 or weighs. Dosing of unfractionated heparin in obese patients with. Dec 02, 2016 however, there are no specific dosing recommendations for doacs in patient with extreme body weight because these agents were not well represented in the clinical trials, and no specific trials examining safety or efficacy in patients of extreme weight have been conducted. This was a retrospective, single center analysis of morbidly obese mo compared to nonobese patients no prescribed apixaban or rivaroxaban for vte or nvaf between august 2016 and august 2017. The majority of obese patients prescribed doacs received standard doses, whereas the use of traditional therapies demonstrated almost onequarter of patients on a. Dosing of direct oral anticoagulants in obese patients. Study intervention weight kg bmi number % of obese patients aristole atrial fibrillation apixaban 5mg bid warfarin na 285 285 bmi.
Hence, there may be at least 70 000 extremely obese patients in the. Deep vein thrombosis dvt and pulmonary embolism pe treatment. Apixaban was the most commonly used anticoagulant in each class, followed by rivaroxaban. Our institution developed an inpatient protocol with reduced enoxaparin doses 0. Anticoagulating obese patients in the modern era patel. In 2002, scholten et al compared enoxaparin 30 mg twice daily vs enoxaparin 40 mg twice daily in a population consisting of 481 patients. The us fda requires a risk evaluation and mitigation strategy rems for apixaban. Eliquis apixaban dosing, indications, interactions. The study reported that none of the patients who had available clinical data n 2238 had recurrent vte or stroke, though information surrounding follow. Anticoagulant therapies and outcomes in obese patients. May 24, 2019 present data for a cohort of 795 morbidly obese patients bmi. Direct oral factor xa inhibitors in patients with morbid obesity the.
The major outcome was the composite of new or recurrent vte, stroke. Apixaban is a novel oral direct factor xa inhibitor that. Age 80 years or olderbody weight 60 kg or lessserum creatinine 1. Pdf dosing of direct oral anticoagulants in obese patients. The lmwh agent enoxaparin lovenox has no official dosing recommendations for these patients,3 but data in this population suggest that a reduced weightbased dose less than 1 mg per kg is. Data on the clinical efficacy and safety of doacs in obese patients are limited. Kido and ngorsuraches also showed no difference in ischemic stroke or major bleeding in doacs compared with warfarin in morbidly obese patients with af. Currently, four doacs dabigatran, rivaroxaban, apixaban, and. Apixaban and rivaroxaban any dose over 8 hours after taking high dose. The anticoagulant effect of apixaban can be expected to persist for at least 24 hours after the last dose i. Use of the direct oral anticoagulants in obese patients. Proposed mechanism activity of the endocannabinoid system in obese patients 1. Four doacs are approved for clinical use in canada.
The 2012 chest guidelines suggest monitoring therapy with antixa levels for obese patients but no definition of obesity is given. While obese patients with vte face an increased risk of recurrence, physicians typically resist prescribing doses two to three times the usual dose because of. Antiarrhythmic and doac dosing in obesity american. Deep vein thrombosis prophylaxis after hip or knee replacement. Effect of extremes of body weight on the pharmacokinetics. Backgroundvitamin k antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Outcomes with novel oral anticoagulants in obese patients. Efficacy and safety of apixaban versus warfarin in. Characteristics of patients prescribed the standard and reduced apixaban doses are shown in table viii in the onlineonly data supplement. Weighing the options for anticoagulation in obesity. Apr 02, 2015 to determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index bmi of 35 kgm2 or greater following one of two bariatric surgical procedures preoperative versus postoperative vertical sleeve gastrectomy or rouxeny gastric bypass patients. Noac prescription were available for 1144 patients 85%.
If anticoagulation with apixaban must be discontinued for a reason other than pathological bleeding, coverage with another anticoagulant should be strongly considered see dosing considerations. Multiple studies have found decreased mortality among obese patients compared to nonobese patients with vte ii. Direct oral anticoagulants in extremely obese patients. Apixaban is an oral, direct factor xa inhibitor that inhibits both free and clotbound factor xa, and has been approved for clinical use in several thromboembolic disorders, including reduction of stroke risk in nonvalvular atrial fibrillation, thromboprophylaxis following hip or knee replacement surgery, the treatment of deep vein thrombosis or pulmonary embolism, and prevention of recurrent. Apixaban in patients with atrial fibrillation nejm. Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Currently, four doacs dabigatran, rivaroxaban, apixaban, and edoxaban. The 2012 chest guidelines suggest monitoring therapy with antixa levels for. Additionally, the dosing of apixaban and rivaroxaban for patients was not. In amplify, patients in the eliquis arm received eliquis 5 mg twice daily for 6 months.
This limits the strength of conclusions about the safety and efficacy of rivaroxaban in the extremely obese patients. To our knowledge, the only clinical trial that addresses the question of apixaban use for venous thromboembolism in patients with impaired renal function is. We investigated clinical outcomes of vte recurrence, stroke and bleeding in morbidly obese patients on apixaban. Update on the use of doacs in obese patients thrombosis uk. Doacsdabigatran, apixaban, edoxaban and rivaroxaban are approved for the treatment of venous thromboembolism vte, prevention of. Increased body weight is associated with 30% lower exposure to standard doses of doacs, raising concerns about adequate dosing in obese. Body size is typically defined using body mass index bmi table 1. People who take eliquis, and have medicine injected into their spinal and epidural area, or have a spinal puncture have a risk of forming a blood clot that can cause longterm or permanent loss of the ability to move paralysis. Weighing the options for anticoagulation in obesity caitlin s.
Evaluation of antixa levels in morbidly obese patients. Treatment of venous thromboembolism in patients who are. Drugs that commonly require dose adjustment in obese patients include lowmolecularweight heparins, 8 aminoglycoside antibiotics, 9 some anaesthetics, 10 monoclonal antibodies and chemotherapeutics. Mar 14, 20 while traditional anticoagulant therapy often requires pharmacodynamic pd monitoring e. Discuss dosing and monitoring strategies when using low molecular weight heparin outline evidence and recommendations for utilization of direct oral anticoagulants. Despite recommendations advising against the use of doacs for acute vte in morbidly obese patients, practice patterns in alberta indicate substantial usage of doacs in obese patients. Given the limitations of its findings, this study does not increase our comfort to use doacs in extremely obese patients. A clinical experience using the plasmatic drug evaluation vincenzo russo, 1 andrea paccone, 2 anna rago, 1 valeria maddaloni, 3 dario iafusco, 4 riccardo proietti, 5 umberto atripaldi, 3 antonio donofrio, 1 paolo golino, 1 and gerardo nigro 1. The use of anticoagulants in morbidly obese patients via medica. Apixiban 5mg or less dose or rivaroxaban 10mg or less dose. To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index bmi of 35 kgm2 or greater following one of two bariatric surgical procedures preoperative versus postoperative vertical sleeve gastrectomy or rouxeny gastric bypass patients.
A new anticoagulant blood thinner that reduces the risk of stroke blood. However, there are no specific dosing recommendations for doacs in patient with extreme body weight because these agents were not well represented in the clinical trials, and no specific trials examining safety or efficacy in patients of extreme weight have been conducted. The safety and effectiveness of the reduced dose of apixaban appeared to be unchanged from the standard dose of apixaban in patients with. Apixaban over 5 mg dose within last 8 hours, rivaroxaban over 10mg dose within last 8 hours thrombolytic therapy. Background vitamin k antagonists have been shown to prevent stroke in patients with atrial fibrillation. Evidence from the pivotal trials of doacs suggests that current dosing is safe and effective in obese patients, suggesting that an obesity paradox is present in patients with af. Comparative efficacy and safety associated with apixaban and. Inhibition of cardiac myocyte and fibroblast death 5. Clarification for apixaban dosing in patients with. No dose adjustments for patients with renal impairment, including those with endstage renal disease esrd on. Of note, the obese patients were significantly younger, but without difference in cha 2 ds 2vasc score overall average 2.
Eliquis apixaban is not for patients with artificial heart valves. The prevalence of obesity is increasing worldwide, and obesity is a known risk factor. Due to its constantly growing incidence, obesity is an increasingly serious social and medical problem. There was no significant difference in individual anticoagulant choice by bmi class. For patients receiving eliquis doses of 5 mg or 10 mg twice daily, when eliquis is coadministered with drugs that are combined pgp and strong cyp3a4 inhibitors e. The effect of obesity on the pharmacokinetics of enoxaparin is not clearly understood and traditional treatment doses in morbidly obese patients body mass index bmi 40 kgm2 can lead to over anticoagulation. Use is not recommended moderate to severe hepatic impairment associated with coagulopathy and clinically relevant bleeding risk. Apixaban, like other anticoagulants, is contraindicated in patients at high risk for bleeding pregnantbreastfeeding.
In the apixaban group, 1034 44% patients were prescribed the standard dose 5 mg twice a day, and 17 56% patients were prescribed the reduced dose 2. Sep 20, 2019 nonvalvular atrial fibrillation patients. Apr 15, 2018 the lmwh agent enoxaparin lovenox has no official dosing recommendations for these patients,3 but data in this population suggest that a reduced weightbased dose less than 1 mg per kg is. Apr 15, 2018 to our knowledge, the only clinical trial that addresses the question of apixaban use for venous thromboembolism in patients with impaired renal function is the amplify study. Apixaban oral tablet is a prescription drug used to treat and prevent blood clots such as deep vein thrombosis dvt and pulmonary embolism pe. Apixaban pharmacokinetics in bariatric patients apb. The data, which are available on the use of novel oral anticoagulants in morbidly obese and. However, due to small cohorts, further investigation is required for those weighing 120 kg or with a bmi. Discuss why obese patients require different dosing strategies of parenteral anticoagulants than non.
No meal requirements or food restrictionsfood does not affect the bioavailability of eliquis. Discontinue eliquis in patients with active pathological hemorrhage. Safety of doacs in patients of extreme weight blood. While traditional anticoagulant therapy often requires pharmacodynamic pd monitoring e. Department of internal medicine, university of utah, usa. Increased risk of major bleeding in underweight patients. Monitoring of apixaban in a super obese patient the american. Antiarrhythmic and doac dosing in obesity medpage today. Dec 24, 2018 in 2016, the international society on thrombosis and haemostasis isth published a guidance document, use of the direct oral anticoagulants in obese patients. However, many patients are not suitable candidates for or are unwilling to receive vitamin k. In patients undergoing knee replacement surgery, the recommended duration of treatment is 12 days. Direct oral factor xa inhibitors in patients with morbid obesity. In 2016, the international society on thrombosis and haemostasis isth published a guidance document, use of the direct oral anticoagulants in obese patients.
Aggressive weightbased dosing guidelines help achieve prompt therapeutic anticoagulation in patients with venous thromboembolism vte. Aug 16, 2011 anticoagulating obese patients in the modern era. The initial dose should be taken 12 to 24 hours after surgery. Antiarrhythmic and doac dosing in obesity american college of. If a patient is on dialysis and is above the age of 80 or weighs under 60 kg then the dose is reduced to 2.
Outcomes associated with apixaban use in patients with end. Apixaban s package insert states that patients with atrial fibrillation may receive full dose apixaban 5 mg twice daily while on hemodialysis as long as they are under the age of 80 and weigh above 60 kg. Dec 15, 2010 aggressive weightbased dosing guidelines help achieve prompt therapeutic anticoagulation in patients with venous thromboembolism vte. Comparative efficacy and safety associated with apixaban. Anticoagulation dosing at ucdmc indication agent standard.
859 1194 266 1271 878 748 1002 440 441 1183 1004 657 442 1450 650 137 835 228 1202 1450 392 708 1048 1193 609 760 679 1355 706 1184 164 1158 1358 335 91 440 1299 364 737 658 839